AvenCell Therapeutics secures $47M from Ligand Pharmaceuticals for Series C financing and CAR-T drug development, with funding tied to clinical milestones.
Amount Raised
$47 Million
Round Type
Series C
CambridgeBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
AvenCell Therapeutics, a clinical-stage CAR-T therapy developer, announced a $47 million financing agreement with Ligand Pharmaceuticals on September 24, 2026. The deal comprises $6 million committed to AvenCell's Series C financing round and $41 million for drug development programs. The larger commitment is structured in tranches, with the first payment due at closing and three additional tranches contingent on predetermined clinical milestones and financing conditions. In return, Ligand will receive royalty interests ranging from mid-single-digit to low-double-digit royalties on AvenCell's products if they succeed commercially.
Quick answer
AvenCell Therapeutics raised $47 Million in a Series C round, dated September 27, 2026. Investors: Ligand Pharmaceuticals. AvenCell Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did AvenCell Therapeutics raise?
- AvenCell Therapeutics raised $47 Million in a Series C round on September 27, 2026.
- Who invested in AvenCell Therapeutics?
- Ligand Pharmaceuticals is named as investors in this round.
- What does AvenCell Therapeutics do?
- AvenCell Therapeutics, Inc. is a leading clinical-stage cell therapy company that focuses on advancing autologous and allogeneic switchable CAR-T cell therapies.
- Where is AvenCell Therapeutics based and how big is it?
- AvenCell Therapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 63 employees.
- Who are the decision-makers at AvenCell Therapeutics?
- Fundz holds 2 contacts at AvenCell Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as AvenCell Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Alethio raised $90M (Series A) on November 5, 2026.
- StimCardio raised $30M (Series A) on October 29, 2026.
- Tivic raised $85M (Series B) on October 27, 2026.
- Tivic raised $8.4M (Series B) on October 8, 2026.
- Rouge Therapeutics raised $58M (Series A) on October 6, 2026.
- Omnio raised $3.3M (Seed) on October 2, 2026.
Who to call at AvenCell Therapeutics, and when
A new round usually means AvenCell Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AvenCell Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AvenCell Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AvenCell Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AvenCell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
AvenCell Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.